![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 1, 2024
A new trial in sarcoma; MSI testing for gastroesophageal cancer; Spring Group Meeting and ASCO highlights
May 1, 2024
This randomized phase 3 trial is comparing treatment with chemotherapy alone or with immunotherapy
May 1, 2024
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
May 1, 2024
Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the 2024 ASCO Annual Meeting
May 1, 2024
Summaries of recently published ECOG-ACRIN research results
May 1, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 9, 2024
A new trial in glioblastoma; leadership transitions; upcoming Group Meeting highlights
April 11, 2024
This phase 2 imaging biomarker trial is evaluating whether novel biomarkers can accurately identify which patients will have better vs. worse survival outcomes early in their disease course
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
March 7, 2024
Big data projects near activation; APP Working Group builds momentum; ECOG-ACRIN welcomes Winn CILA scholar